<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274803</url>
  </required_header>
  <id_info>
    <org_study_id>INTRALIPID-APS</org_study_id>
    <nct_id>NCT04274803</nct_id>
  </id_info>
  <brief_title>Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?</brief_title>
  <official_title>Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will address the value of adding intralipid infusion in reducing pregnancy
      complications related to antiphospholipid syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in the Department of Obstetrics and Gynecology, Tanta University
      on patients attending the antenatal care clinic and also on patients attending the
      researchers private clinics for antenatal care. The number of patients enrolled in the study
      will be 105 patients after application of inclusion and exclusion criteria.

      All women wil be thoroughly informed about the study aims and through discussion about the
      procedure, associated benefits and risks and will sign a written consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal loss</measure>
    <time_frame>within 9 months</time_frame>
    <description>Fetal demise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Premature delivery</measure>
    <time_frame>Before 37 weeks</time_frame>
    <description>occurrence of preterm labour before 37 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>&gt; 20 weeks</time_frame>
    <description>Hypertesion, proteiuria and or edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fetal growth restriction</measure>
    <time_frame>within 9 months</time_frame>
    <description>Fetal poderal index less than normal</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Antiphospholipid Syndrome in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Intralipid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid, 20% Intravenous Emulsion</intervention_name>
    <description>intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.</description>
    <arm_group_label>Intralipid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy of antiphospholipis syndrome</intervention_name>
    <description>the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.</description>
    <arm_group_label>Standard care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women at booking date who were already diagnosed to have antiphospholipid
             syndrome (APS) .

        Exclusion Criteria:

          -  Patients with gestational age â‰¥ 9 weeks

          -  patients with diagnosed other auto-immune disorder

          -  patients with chronic hypertension, diabetes mellitus, thyroid disorders,

          -  patient with renal diseases

          -  patients who requested to withdraw from the study at any point .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Adel Elgergawy</name>
      <address>
        <city>Tanta</city>
        <zip>3111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adel Elgergawy, MD</last_name>
      <phone>+201002057250</phone>
      <email>dradelali775@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman S Dawood, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>when approved by ethical committee</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>9 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

